GMI 6.6 to HbA1c conversion is a common query for people using continuous glucose monitors (CGMs) to manage diabetes. A Glucose Management Indicator (GMI) of 6.6% is calculated from CGM data and approximates a laboratory HbA1c result, sitting just above the 6.5% diagnostic threshold for diabetes. However, GMI and HbA1c are not identical measures — they are generated differently and can diverge for several clinical reasons. This article explains what a GMI of 6.6% means, how it relates to HbA1c, why the two values may not always match, and when to discuss your results with a healthcare professional.

What Is GMI and How Does It Differ From HbA1c?

GMI is a CGM-derived estimate of average glucose expressed as a percentage, calculated using a validated formula, whereas HbA1c is a laboratory blood test reflecting red blood cell glycation over 8–12 weeks; they are complementary tools, not direct substitutes.

Glucose Management Indicator (GMI) is a calculated estimate of a person's average blood glucose levels, derived from continuous glucose monitor (CGM) data. It was developed to provide a figure that approximates what a laboratory HbA1c result might show, based on the average glucose readings recorded by a CGM device over a defined period. For a GMI value to be considered reliable, international consensus guidance recommends a minimum of 14 days of CGM data with at least 70% sensor wear time (Bergenstal RM et al., Diabetes Care 2018; International Consensus on Time in Range, 2019 and 2023 update).

HbA1c (glycated haemoglobin) is a well-established laboratory blood test that reflects average blood glucose control over the preceding two to three months. It measures the percentage of haemoglobin molecules that have glucose attached to them. In UK laboratories, HbA1c is standardised to the IFCC (International Federation of Clinical Chemistry) method and reported in mmol/mol as well as the older NGSP percentage unit. HbA1c remains central to NICE guidance on diabetes diagnosis and long-term monitoring.

While both GMI and HbA1c aim to reflect average glucose levels, they are generated through fundamentally different methods:

• HbA1c is measured from a venous blood sample in a laboratory, reflecting red blood cell turnover over approximately 8–12 weeks.

• GMI is calculated using a mathematical formula applied to CGM-derived average glucose data. The formula can be expressed as: GMI (%) = 3.31 + 0.02392 × mean glucose (mg/dL), or equivalently, GMI (%) = 3.31 + 0.43056 × mean glucose (mmol/L).

Because of these differences, GMI and HbA1c are complementary tools rather than direct substitutes. Understanding what each measurement represents helps patients and clinicians interpret results more accurately and make informed decisions about diabetes management.

Understanding a GMI of 6.6% and What It Indicates

A GMI of 6.6% corresponds to an estimated average glucose of approximately 7.6 mmol/L, sitting just above the 6.5% (48 mmol/mol) NICE diabetes diagnostic threshold, and should always be interpreted alongside Time in Range and individual clinical targets.

A GMI of 6.6% corresponds to an estimated average glucose of approximately 7.6 mmol/L (roughly 138 mg/dL), calculated using the validated GMI formula (Bergenstal RM et al., Diabetes Care 2018).

To place this in context, it is helpful to understand the relevant HbA1c reference thresholds used in UK clinical practice:

• Below 42 mmol/mol (6.0%) is generally considered within the normal range.

• 42–47 mmol/mol (6.0–6.4%) indicates a high risk of developing type 2 diabetes (sometimes referred to as non-diabetic hyperglycaemia or prediabetes).

• 48 mmol/mol (6.5%) or above is the diagnostic threshold for diabetes, per NICE guidance (NG28).

A GMI of 6.6% sits just above the diabetes diagnostic threshold. For someone already living with type 1 or type 2 diabetes, this figure may reflect reasonably managed average glucose levels, though individual targets are always determined in discussion with a clinician and depend on factors such as age, comorbidities, treatment regimen, and risk of hypoglycaemia.

NICE HbA1c targets for people with diabetes include:

• Type 2 diabetes (not on insulin or a sulfonylurea): aim for 48 mmol/mol (6.5%).

• Type 2 diabetes on insulin or a sulfonylurea: a target of 53 mmol/mol (7.0%) is often appropriate to reduce hypoglycaemia risk.

• Type 1 diabetes: aim for 48 mmol/mol (6.5%), though targets are individualised (NICE NG17).

Key points about a GMI of 6.6%:

• It does not capture glucose variability — two individuals can share the same GMI but have very different patterns of highs and lows throughout the day.

• It should always be interpreted alongside other CGM metrics, such as Time in Range (TIR) — for most adults, the consensus target is ≥70% of time within 3.9–10.0 mmol/L — as well as time below range and time above range (International Consensus on Time in Range, 2019; 2023 update).

• Interpretation should also account for hypoglycaemia burden, glucose variability, age, and any relevant comorbidities.

A GMI of 6.6% is a useful prompt to review lifestyle factors, medication adherence, and whether current treatment targets are being met, in discussion with a healthcare professional.

Why Your GMI and HbA1c Results May Not Match

GMI and HbA1c can diverge due to conditions affecting red blood cell turnover (e.g., anaemia, haemoglobinopathies, CKD), timing differences between the two measures, or individual variation in haemoglobin glycation; discrepancies warrant clinical review.

One of the most common sources of confusion for people using CGM devices is discovering that their GMI and their laboratory HbA1c do not align. This discrepancy is well recognised in clinical practice and can occur for several important reasons.

Biological variation in red blood cells is a primary factor. HbA1c reflects glucose attachment to haemoglobin over the lifespan of red blood cells (approximately 120 days). Conditions that alter red blood cell turnover can cause HbA1c to read falsely high or low, independent of actual glucose levels. These include:

• Haemolytic anaemia, iron deficiency anaemia, or vitamin B12/folate deficiency.

• Haemoglobinopathies (e.g., sickle cell trait or thalassaemia).

• Recent blood transfusion or significant blood loss.

• Chronic kidney disease (CKD) or uraemia, which can affect red blood cell survival.

• Erythropoietin (EPO) therapy, which increases red blood cell turnover.

• Pregnancy and the postpartum period.

• Splenectomy, which prolongs red blood cell lifespan and may falsely elevate HbA1c.

Timing differences also play a role. GMI is calculated from CGM data over a relatively short window (as little as two weeks), whereas HbA1c reflects a longer, weighted average. If glucose control has recently improved or deteriorated, GMI will reflect this change more promptly than HbA1c.

Additional reasons for discordance include:

• CGM calibration or sensor accuracy issues, which may affect the average glucose value used to calculate GMI.

• Individual physiological differences in how glucose binds to haemoglobin, meaning some people consistently show higher or lower HbA1c values than their CGM data would predict.

• Laboratory variability, though UK HbA1c assays are IFCC-standardised and subject to national quality assurance, meaning inter-laboratory variation is generally small.

When GMI and HbA1c diverge — a gap of more than approximately 0.5 percentage points is often used as a pragmatic prompt for clinical review, though this is not a formally defined UK threshold — this warrants further discussion with a clinician to explore potential causes. It is important to note that HbA1c remains the accepted tool for diagnosing diabetes, while CGM-derived metrics including GMI are used to support ongoing management. Both should be considered together, with discrepancies prompting further clinical review rather than immediate concern (NICE NG17; NICE NG28).

How Clinicians Use GMI Alongside HbA1c in Diabetes Care

Clinicians use GMI as part of a broader CGM data review — alongside Time in Range, hypoglycaemia burden, and glucose variability — to complement HbA1c; GMI is not a diagnostic tool and does not replace laboratory testing.

In modern diabetes care, CGM-derived metrics — including GMI — are increasingly used alongside traditional laboratory measures such as HbA1c to build a more comprehensive picture of a patient's glycaemic profile.

NICE guidance supports the use of CGM as follows:

• Type 1 diabetes (NICE NG17): CGM should be offered to all adults with type 1 diabetes.

• Type 2 diabetes (NICE NG28): CGM or flash glucose monitoring should be offered when specific criteria are met — most commonly for people on insulin therapy with particular clinical needs. Local NHS policies may broaden access further.

Clinicians typically use GMI as part of a broader CGM data review, which includes:

• Time in Range (TIR): The percentage of time glucose levels remain within the target range. For most adults with diabetes, the international consensus target is ≥70% of time within 3.9–10.0 mmol/L (International Consensus on Time in Range, 2019; 2023 update).

• Time below range: Periods of hypoglycaemia (below 3.9 mmol/L), which carry significant safety risks.

• Time above range: Periods of hyperglycaemia (above 10.0 mmol/L) linked to long-term complications.

• Glucose variability metrics, such as the coefficient of variation (CV).

When GMI and HbA1c are concordant, clinicians can have greater confidence in their assessment of average glycaemic control. When they diverge significantly, this serves as a pragmatic prompt to investigate potential causes such as haematological conditions or CGM accuracy concerns, rather than a formally defined clinical threshold.

CGM devices used in the UK are CE/UKCA-marked medical devices regulated by the Medicines and Healthcare products Regulatory Agency (MHRA); they are not subject to EMA approval, which applies to medicines rather than medical devices. NHS diabetes services are increasingly integrating CGM data into structured reviews. GMI is not used as a standalone diagnostic criterion for diabetes; HbA1c, fasting plasma glucose, or oral glucose tolerance testing remain the accepted diagnostic tools per NICE guidance. However, GMI serves a valuable role in ongoing monitoring and in supporting shared decision-making between patients and their clinical teams.

When to Discuss Your GMI or HbA1c With Your GP

Contact your GP promptly if your GMI or HbA1c is consistently above target, if there is a significant unexplained discrepancy between the two, or if your CGM data shows frequent hypoglycaemia; seek emergency help for suspected DKA or severe hypoglycaemia.

Understanding your GMI and HbA1c results is an important part of managing diabetes effectively, but knowing when to seek professional advice is equally essential. Both measures provide valuable information, and changes in either should be discussed with your GP or diabetes care team in a timely manner.

Seek urgent emergency help (call 999 or go to A&E) if you experience:

• Severe hypoglycaemia with confusion, seizures, loss of consciousness, or inability to treat yourself.

• Symptoms that may suggest diabetic ketoacidosis (DKA) — particularly in type 1 diabetes — such as persistent high glucose with ketones, vomiting, abdominal pain, rapid or laboured breathing, or increasing drowsiness. DKA is a medical emergency (NHS guidance on diabetic ketoacidosis; NICE NG17).

Contact your GP or diabetes nurse promptly if:

• Your GMI or HbA1c is consistently above your agreed target, despite adherence to your current treatment plan.

• There is a significant and unexplained discrepancy between your GMI and your laboratory HbA1c result.

• Your CGM data suggests frequent or prolonged periods of hypoglycaemia (low blood glucose).

• You have recently been diagnosed with anaemia, a haemoglobin disorder, kidney disease, or another condition that may affect HbA1c accuracy.

• You are experiencing symptoms of poorly controlled diabetes, such as increased thirst, frequent urination, unexplained fatigue, or recurrent infections.

For most people with diabetes, HbA1c is checked every 3–6 months as part of routine NHS diabetes reviews — typically every three months until levels are stable, then every six months — in line with NICE recommendations (NG17; NG28). If you use a CGM device, your GMI data can be shared with your clinical team; many devices allow data to be uploaded directly to clinic systems or reviewed via patient-facing apps.

It is worth remembering that a single GMI or HbA1c reading is rarely the full story. Trends over time, alongside your wider health picture, are what guide clinical decisions. If you are uncertain about what your results mean or how they relate to your treatment targets, your GP, practice nurse, or diabetes specialist nurse is the most appropriate first point of contact. Open, informed conversations about your data lead to better, more personalised care.

Frequently Asked Questions